MGNX (Macrogenics) Total Current Assets : $217.5 Mil (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Macrogenics's total current assets for the quarter that ended in Dec. 2024 was $217.5 Mil.

Macrogenics Total Current Assets Historical Data

The historical data trend for Macrogenics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Total Current Assets Chart

Macrogenics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

312.59

279.56

222.18

251.34

217.49

Macrogenics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Current Assets	Get a 7-Day Free Trial															251.34	202.58	156.95	222.20	217.49

Macrogenics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Macrogenics's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	201.667	+	4.309	+	0	+	11.514
	=	217.5

Macrogenics's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	201.667	+	4.309	+	0	+	11.514
	=	217.5

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Macrogenics (NAS:MGNX) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Macrogenics's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	201.667	-	145.598	+	0.75 * 4.309	+	0.5 * 0
=	59.3

Macrogenics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Macrogenics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Macrogenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

M55:Germany

Address

9704 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.macrogenics.com

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Executives

Jeffrey Stuart Peters	officer: Acting General Counsel	9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
James Karrels	officer: SVP, CFO and Secretary	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Thomas Spitznagel	officer: Sr VP, BPD & Manufacturing	9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Eric Blasius Risser	officer: Sr VP & Chief Business Officer	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Ezio Bonvini	officer: Sr VP, Research & CSO	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz	director
Margaret Liu	director	C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra	director	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
William K Heiden	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kenneth Galbraith	director	OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck	officer: Chief Medical Officer	12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949